Search - tctmd.com

Displaying 381 - 400 of 550

Sort: Relevancy | Date

News Features

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

Shelley Wood

October 22, 2018

News Daily News

Elevated Lp(a), Even in Statin-Treated Patients, Linked With Higher CVD Risks

Michael O'Riordan

October 15, 2018

News Daily News

Statin Benefits: Yes for CVD but No for Everything Else, Says New Review

Michael O'Riordan

October 08, 2018

News Conference News TCT 2018

Statin Preloading Benefit More Pronounced in STEMI Patients: SECURE-PCI

Michael O'Riordan

October 05, 2018

News Daily News

In Type 2 Diabetes, Five Risk Factor Targets Keep MI, Stroke, and Death in Check

Caitlin E. Cox

August 15, 2018

News Daily News

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

Michael O'Riordan

August 02, 2018

News Daily News

All-Cause Death Not Increased With Febuxostat Among Medicare Patients With Gout

Caitlin E. Cox

June 19, 2018

News Daily News

Serial CTA Shines a Light on Statin Effects in Subclinical CAD

Yael L. Maxwell

June 15, 2018

News Daily News

Among African Americans in Need of LDL Lowering: Less Statin Use, More Distrust of Doctors

Michael O'Riordan

June 13, 2018

News Conference News EAS 2018

ORION 1 Data Show Lipoprotein-Lowering Beyond LDL Cholesterol With Injectable Inclisiran

Yael L. Maxwell

May 14, 2018

News Conference News EAS 2018

EAS Consensus Document Examines Safety of Statins Beyond Muscle Symptoms

Yael L. Maxwell

May 11, 2018

News Daily News

PREDICT-1° CVD Risk Calculator, Based on Present-Day Patients, Beats ACC/AHA ‘Pooled Cohort’ Equations

Michael O'Riordan

May 10, 2018

News Conference News EAS 2018

Unlocking Lp(a): Baseline Levels Matter, but So Too Does Absolute Reduction

Yael L. Maxwell

May 08, 2018

News Conference News EAS 2018

Can Clinicians Really Put a Stop to Atherosclerosis? Experts Explore the How and When of CVD Prevention

Yael L. Maxwell

May 07, 2018

Presentation EAS 2018

Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial

Presenter: Michelle L. O’Donoghue

May 07, 2018

Presentation EAS 2018

LPA variants, risk of coronary disease, and estimated clinical benefit of lipoprotein(a) lowering therapies: a Mendelian randomization analysis

Presenter: Brian A. Ference

May 07, 2018

News Daily News

Alirocumab Price Slashed in Deal With Express Scripts

Michael O'Riordan

May 03, 2018

News Daily News

The Higher the LDL, the Bigger the Mortality Benefit of Intensive Therapy: Meta-analysis

Michael O'Riordan

April 20, 2018

News Daily News

Pills or Even Tea More Palatable Than Exercise for the Treatment of Hypertension, US Adults Say

Michael O'Riordan

April 09, 2018

News Daily News

Costs of Atherosclerotic CVD Cripple Low-Income Families, Even With Insurance

Shelley Wood

April 06, 2018

Advertisement

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

Elevated Lp(a), Even in Statin-Treated Patients, Linked With Higher CVD Risks

Statin Benefits: Yes for CVD but No for Everything Else, Says New Review

Statin Preloading Benefit More Pronounced in STEMI Patients: SECURE-PCI

In Type 2 Diabetes, Five Risk Factor Targets Keep MI, Stroke, and Death in Check

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

All-Cause Death Not Increased With Febuxostat Among Medicare Patients With Gout

Serial CTA Shines a Light on Statin Effects in Subclinical CAD

Among African Americans in Need of LDL Lowering: Less Statin Use, More Distrust of Doctors

ORION 1 Data Show Lipoprotein-Lowering Beyond LDL Cholesterol With Injectable Inclisiran

EAS Consensus Document Examines Safety of Statins Beyond Muscle Symptoms

PREDICT-1° CVD Risk Calculator, Based on Present-Day Patients, Beats ACC/AHA ‘Pooled Cohort’ Equations

Unlocking Lp(a): Baseline Levels Matter, but So Too Does Absolute Reduction

Can Clinicians Really Put a Stop to Atherosclerosis? Experts Explore the How and When of CVD Prevention

Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial

LPA variants, risk of coronary disease, and estimated clinical benefit of lipoprotein(a) lowering therapies: a Mendelian randomization analysis

Alirocumab Price Slashed in Deal With Express Scripts

The Higher the LDL, the Bigger the Mortality Benefit of Intensive Therapy: Meta-analysis

Pills or Even Tea More Palatable Than Exercise for the Treatment of Hypertension, US Adults Say

Costs of Atherosclerotic CVD Cripple Low-Income Families, Even With Insurance

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content